BPC-157 — complete EU guide.
Body Protection Compound-157 is a synthetic pentadecapeptide derived from a protein found in gastric juice. It is the most-searched research peptide in Europe.
- Synthetic 15-amino-acid partial sequence of a protein found in human gastric juice; unusually stable in gastric acid.
- Most replicated findings are accelerated tendon-to-bone and ligament healing in animal models.
- Strong rodent evidence for gastrointestinal mucosal protection — the research area where BPC-157 originated.
- No completed human clinical trials; systemic and neurological claims rest on animal data only.
- Banned in professional sport and not approved by any regulator; research compound only.
What is BPC-157?
BPC-157 is a synthetic peptide of 15 amino acids — a partial sequence of a protein found in human gastric juice. Unlike many research peptides it is stable in gastric juice, which explains interest in both oral and injectable forms. It is not an approved pharmaceutical anywhere and is sold by EU research vendors for laboratory research only.
What does the research show?
What to look for when buying in Europe
Minimum purity ≥98% HPLC with mass-spec identity confirmation. Demand a batch-specific COA from a named third-party lab. Lyophilized BPC-157 is stable at room temperature for weeks but ships best with cold packs over longer distances.
Molecular information
Pharmacokinetics
Compare BPC-157 across EU suppliers
14 EU vendors · COA-verified · from €18.85 · Updated monthly
Frequently asked questions
What is BPC-157? ▾
BPC-157 is a synthetic peptide of 15 amino acids, a partial sequence of a body-protection compound found in human gastric juice. It is studied for tissue repair and gastrointestinal protection but is not an approved medicine anywhere.
Does BPC-157 actually heal injuries? ▾
Animal studies consistently show accelerated tendon, ligament and gut healing, and tendon-to-bone repair is its most replicated finding. However, there are no completed human clinical trials, so human efficacy is not scientifically established.
Is BPC-157 approved or legal? ▾
It is not approved by the FDA, EMA or any regulator. In most EU countries it is sold as a research chemical for laboratory use only, not for human or animal consumption.
Can BPC-157 be taken orally? ▾
Because the parent compound is stable in gastric juice, both oral and injectable forms are discussed in the research. Oral stability is one reason it attracted interest, but human dosing data does not exist and we do not provide administration advice.
What does the gut research show? ▾
Rodent models show protective effects on gastric mucosa, ulcer healing and inflammatory bowel models. This is the original and most robust area of BPC-157 research.
Is BPC-157 safe? ▾
Animal studies report a favourable safety profile and only small human pilot reports exist. Without completed clinical trials, the human safety profile is not established.
Is BPC-157 banned in sport? ▾
Yes. It appears on anti-doping prohibited lists and its use is banned in professional sport.
How do I verify BPC-157 quality? ▾
Require a batch-specific COA from a named third-party lab showing ≥98% HPLC purity with mass-spec identity confirmation. Lyophilised BPC-157 is relatively stable but ships best cold over long distances.
Why is BPC-157 often researched with TB-500? ▾
They are studied together for complementary tissue-repair mechanisms — BPC-157 for angiogenesis and gut/tendon effects, TB-500 for actin regulation and cell migration. This is a research observation, not a usage recommendation.
References
- Rat study showing BPC-157 promoted Achilles tendon-to-bone healing and counteracted corticosteroid-impaired healing. Krivic A, et al. J Orthop Res. 2006;24(5):982–989. DOI PubMed 16583442
- In-vitro work showing BPC-157 accelerates tendon fibroblast outgrowth, survival and migration via the FAK-paxillin pathway. Chang CH, et al. J Appl Physiol. 2011;110(3):774–780. DOI PubMed 21030672
- Systematic review of BPC-157 in orthopaedic sports medicine summarising preclinical efficacy and the lack of FDA approval. Vasireddi N, et al. HSS J. 2025;21(4):485–495. DOI PubMed 40756949